Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery

Figure 1

Distributions of malignant and benign tumors among patients with evaluated biomarker kinetics (PDAC: pancreatic ductal adenocarcinoma; NET: pancreatic neuroendocrine tumor; MAC: mucinous cystadenocarcinoma; AVC: ampulla of Vater carcinoma; DBDC: distal bile duct carcinoma; IPMN: intraductal papillary mucinous neoplasm; BT: benign tumor; IH: inconclusive histology).